- Last Close 23
- Sector Healthcare
- Industry Biotechnology
- Investment Style Small Growth
- Day Range 22.60 – 23.04
- Year Range 18.05 – 31.78
- Market Cap 3.0712 Bil
- Volume / Avg 896,444.0 / 1.1 Mil
- Price / Sales 1.96
- Price / Book 1.48
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis VIR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile VIR
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
San Francisco, CA, 94158
Related Articles VIR
COVID-19 Sales Have No Major Impact on Drug and Vaccine Manufacturers We Cover
FAQs for Vir Biotechnology Inc Stock
No. VIR does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
VIR’s market cap is 3.07 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
VIR’s stock style is Small Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
VIR’s price/sales is 1.96.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.
VIR’s price/forward earnings is 6.01.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.
VIR’s price/book is 1.47.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.
See VIR’s valuation ratios compared to the Market Index.
VIR’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare VIR’s historical performance against its industry peers and the overall market.